HC Wainwright reissued their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN – Free Report) in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a $17.00 price target on the biopharmaceutical company’s stock.
Palatin Technologies Trading Up 2.9 %
Palatin Technologies stock opened at $2.11 on Thursday. Palatin Technologies has a 12-month low of $1.43 and a 12-month high of $5.65.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.36). Palatin Technologies had a negative return on equity of 583.06% and a negative net margin of 445.12%. The business had revenue of $2.03 million for the quarter, compared to analysts’ expectations of $2.28 million. During the same period last year, the firm earned ($0.13) earnings per share. As a group, analysts forecast that Palatin Technologies will post -2.36 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Featured Stories
- Five stocks we like better than Palatin Technologies
- What Are Dividend Challengers?
- MarketBeat Week in Review – 4/29 – 5/3
- What Are Dividend Champions? How to Invest in the Champions
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Consumer Staples Stocks, Explained
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.